z-logo
Premium
Effects of ketorolac tromethamine on hemostasis in volunteers
Author(s) -
Conrad Kenneth A,
Fagan Timothy C,
Mackie Mary J,
Mayshar Paula V
Publication year - 1988
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1988.70
Subject(s) - ketorolac tromethamine , hemostasis , ketorolac , medicine , pharmacology , anesthesia , analgesic
Ketorolac tromethamine, an analgesic agent with prostaglandin synthetase–inhibiting activity, is more active than aspirin in vitro in inhibiting collagen– or arachidonic acid–induced platelet aggregation. In this randomized, double‐blind study, 26 volunteers received ketorolac, 30 mg intramuscularly four times a day for 5 days, and placebo, two capsules orally four times a day for at the last 2 study days. The effects of this treatment were compared with those of intramuscular placebo and oral aspirin, two 325 mg capsules, given on the same schedule to eight volunteers. Aspirin at a mean serum concentration of 84 μg/ml did not affect prothrombin time, partial thromboplastin time, platelet count, or bleeding time. Ketorolac produced a modest prolongation of the bleeding time, from 4.9 ±1.1 minutes (mean ± SD) to 7.8 ± 4.0 minutes (p < 0.005). Ketorolac did not affect the prothrombin time or partial thromboplastin time but was associated with clinically insignificant change in the platelet count from 303 ± 57 × 10 3 /m 3 to 277 ± 56 × 10 3 /mm 3 . Clinical Pharmacology and Therapeutics (1988) 43, 542–546; doi: 10.1038/clpt.1988.70

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here